February 2, 2022 – CounterX Therapeutics

February 2, 2022 in Publications

The Journal of Pharmacology and Experimental Therapeutics: Pharmacological Profiling of Antifentanyl Monoclonal Antibodies in Combination with Naloxone in Pre- and Postexposure Models of Fentanyl Toxicity

Baehr CA, Wu MM, Pandit SG, Arias-Umana J, AuCoin D, Pravetoni M. J Pharmacol Exp Ther. 2022 May;381(2):129-136. doi: 10.1124/jpet.121.001048. PMID: 35153198

CounterX Therapeutics Announces Publication Demonstrating CTRX-101, an Anti-Fentanyl Monoclonal Antibody Therapy, Reverses Fentanyl-Induced Overdose in Preclinical Model

An anti-fentanyl monoclonal antibody reverses fentanyl-induced apnea in pigs

Psychopharmacology: A humanized monoclonal antibody attenuates fentanyl self-administration and reverses and prevents fentanyl-induced ventilatory depression in rhesus monkeys

ACS Omega: Structure-Based Engineering of Monoclonal Antibodies for Improved Binding to Counteract the Effects of Fentanyl and Carfentanil

The Journal of Immunology: Monoclonal Antibodies Engineered with Fc Region Mutations to Extend Protection against Fentanyl Toxicity

Expert Opinion Investigational Drugs: The potential role of opioid vaccines and monoclonal antibodies in the opioid overdose crisis

The Journal of Pharmacology and Experimental Therapeutics: Pharmacological Profiling of Antifentanyl Monoclonal Antibodies in Combination with Naloxone in Pre- and Postexposure Models of Fentanyl Toxicity